Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.

Cogent Biosciences (COGT): The 500% Miracle Drug and the Smart Money's Quiet Exit

2026-04-01BearishStrongChange from report: -9.1%1M: +3.9%3M: +9.2%

Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.